Evolution of B-Cell Malignancy Therapy and Treatment Resistance: Where Are We Headed?
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 July 2024 | Viewed by 452
Special Issue Editors
Interests: B-cell malignancy; drug resistance; novel therapy
Interests: chronic lymphocytic leukemia; mantle cell lymphoma; non-hodgkin lymphoma
Special Issue Information
Dear Colleagues,
Advances in our understanding of B-cell neoplasm biology, genetics, and immunology have allowed for the identification of new therapeutic targets and the emergence of bispecific antibodies, CAR T-cell therapies, and novel small-molecule inhibitors. However, outcomes for relapsed and/or refractory lymphoma, myeloma, and CLL with therapy resistance remain inadequate for most patients. Thus, an unmet need exists for the development of novel and effective therapeutic strategies based on lymphoma biology and resistance mechanisms. In this Special Issue, we will focus on the changing therapeutic landscape of B-cell malignancies, from chemoimmunotherapy to targeted agents and immunotherapeutic approaches, and the evolutionary trajectories of treatment resistance. We will provide perspectives and evidence-based rationale for novel combinatorial strategies to synergistically and reciprocally overcome treatment resistance, enhance clinical efficacy, and improve patient outcomes.
Prof. Dr. Jianguo Tao
Guest Editor
Prof. Dr. Michael E. Williams
Dr. Jeffrey W. Craig
Co-Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- B-cell malignancy
- drug resistance
- novel therapy
- TME
- chemoimmunotherapy
- targeted agents
- immunotherapeutic approaches
